Calidi Biotherapeutics
Business Services · California, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
4475 Executive Dr Ste 200, San Diego, Ca...Phone Number
(858) 794-9600Website
www.calidibio.comRevenue
-Stock Symbol
CLDIIndustry
ZI Rank: 1
Signal Type
Mar
Apr
May
Jun
Jul
Aug
ZI Rank
2
1
1
2
1
1
About Calidi Biotherapeutics
Calidi Biotherapeutics is a clinical-stage immuno-oncology company with proprietary technology that is revolutionizing the effective delivery and potentiation of oncolytic viruses for targeted therapy against difficult-to-treat cancers. Calidi Biotherapeutics is advancing a potent allogeneic stem cell and oncolytic virus combination for use in multiple oncology indications. Calidi's off-the-shelf, universal cell-based delivery platforms are designed to protect, amplify, and potentiate oncolytic viruses currently in development leading to enhanced efficacy and improved patient safety. Calidi Biotherapeutics is headquartered in San Diego, California.Explore more
Calidi Biotherapeutics Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Calidi Biotherapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check if Calidi Biotherapeutics has recently received funding, and reach out quickly before it becomes old news!
Product Launch: Get notified when Calidi Biotherapeutics launches new products
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Calidi Biotherapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Congratulate Masked Content for being promoted to Masked Content at Calidi Biotherapeutics
Earning: See what the market has to say on Calidi Biotherapeutics recently announced quarterly report
Website visits: Recent activity has been detected on your website
Click to see if Calidi Biotherapeutics had a recent Job posting/layoffs
Check out if Calidi Biotherapeutics is spiking on competitors!
Funding: Get notified immidiatlly once Calidi Biotherapeutics has new funding data
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 3 more new buyers
Compare Similar Companies to Calidi Biotherapeutics
Compare insights from companies similar to Calidi Biotherapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Calidi Biotherapeutics is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Calidi Biotherapeutics is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Calidi Biotherapeutics.
Calidi Biotherapeutics financials insights
Gather financial insights about Calidi Biotherapeutics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2020
Debt
$150K
2023
Series B
$25M
Calidi Biotherapeutics Tech Stack
A closer look at the technologies used by Calidi Biotherapeutics
See more technologies
Most Recent Scoops
Person-Based
Medical Research
Person-Based
Funding
, a clinical‐stage immuno-oncology company, has secured an undisclosed amount of Series A funding. Backers included Won & Partners and Greentable Co., Ltd.
Funding
Earnings
Earnings, Finance
New Hire
Executive Move
Executive Moves, New Hire, Board of Directors
Calidi Biotherapeutics News & Media
Calidi Biotherapeutics Announces $1.2 Million Registered Direct Offering
SAN DIEGO, Sept. 17, 2026 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE American: CLDI) (“Calidi” or the “Company”), a biotechnology company pioneering the development of targeted genetic medicines, today announced that it has entered into a definitive stock purchase agreement with certain accredited investors and/or qualified institutional buyers for the purchase and sale of 1,025,640 shares of the Company’s common stock, in a registered direct offering, at a per share purchase price oCalidi Biotherapeutics to Participate in the H.C. Wainwright 28th Annual Global Investment Conference
SAN DIEGO, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics Inc. (NYSE American: CLDI) (“Calidi” or the “Company”), a biotechnology company pioneering the development of targeted genetic medicines, today announces that it will participate in the H.C. Wainwright 28th Annual Global Investment Conference. The conference is being held on September 14 – 16, 2026 at the Lotte New York Palace Hotel.Calidi Biotherapeutics Reports Second Quarter 2026 Financial Results and Recent Business Highlights
Received positive pre-IND feedback from the U.S. FDA for CLD-401, indicating agreement on the current development strategy toward a first-in-human study targeting first patient dosing in Q1 2027Calidi Biotherapeutics Presents New Data on Cytotoxicity and IL-15 SA Expression in Human and Murine Tumor Cells at the American Association for Cancer Research Drug Discovery and Development Conference
SAN DIEGO, July 27, 2026 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE American: CLDI) (“Calidi” or the “Company”), a clinical-stage biotechnology company pioneering the development of systemically delivered, targeted genetic medicines, presented on July 23, 2026, at the American Association for Cancer Research Drug Discovery and Development (AACR D3) Conference in Boston, MA. The Company presented new data on its CLD-401 program that it expects to enter the clinic in the first quarter
Read more news
Top Business Services Companies
Top companies in Canada by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Calidi Biotherapeutics
Sign Up For FreeTo access detailed company insights
Calidi Biotherapeutics is a clinical-stage immuno-oncology company with proprietary technology that is revolutionizing the effective delivery and potentiation of oncolytic viruses for targeted therapy against difficult-to-treat cancers. Calidi Biotherapeutics is advancing a potent allogeneic stem cell and oncolytic virus combination for use in mult... Read More
